Taken together, our study shows that the gut microbial-derived metabolite butyrate can enhance the efficacy of anti-PD-1 immunotherapy by modulating the T cell receptor signaling of cytotoxic CD8 T cells, suggesting that butyrate is a promising biomarker to sufficiently improve therapeutic efficacy in cancer patients. This evidence concerns the gene PDCD1 and cancer.